Vitae Biomedical Targets Lung Cancer with Innovative Urine Testing Platform

Vitae Biomedical Co., Ltd. is a pioneering biotech company dedicated to advancing cancer detection technologies, particularly in lung health. Focused on democratizing access to screenings, the company aims to establish itself as a global leader in health management solutions.

In Taiwan, expenditures on "Trachea, Bronchus, and Lung Cancer" consistently rank highest among major cancers, totaling 24 billion points last year (2023), excluding out-of-pocket costs. Despite this financial investment, lung cancer remains the primary cause of cancer-related deaths, highlighting its severity and global challenges. Diagnosis often occurs at advanced stages, a widespread issue.

Our flagship product, "Urine-based Lung Cancer Antigen Detection Kits," assists physicians in managing lung nodules, reducing false positives and unnecessary invasive procedures. Particularly valuable in regions with limited healthcare access, this technology serves as a robust tool for initial screening and ongoing monitoring, effectively mitigating the threat of lung cancer.

Grounded in a "people-first, health-focused" philosophy, Vitae Biomedical's development of urine-based technology reflects a deep commitment to improving human health. By lowering testing barriers and easing diagnostic uncertainties, we aim to promote widespread early disease detection. To learn more, visit us at BioAsia 2024, Booth M636 in the Nangang Exhibition Center, where we welcome discussions about our vision and innovations.

Venue: Taipei Nangang Exhibition Center, Hall 1, 4F
Date: July 25th (Thu) - 28th (Sun), 2024
Booth: Ministry of Science and Technology(NSTC) / Southern Taiwan Science Park: No. M636